Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

James Mullen

Hand Surgery Wexford, PA Medical Doctor

NPI 1649614041 CMS profile 7226790

6001 Stonewood Dr, Wexford, PA 15090

Open in the dashboard

General payments

$42,660

127 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, James Mullen of Wexford, PA is reported in the CMS Open Payments database as having received $42,660 across 127 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Hand Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,528 15
2024 General $13,712 46
2023 General $2,270 9
2022 General $11,994 14
2021 General $10,116 18
2020 General $1,549 19
2019 General $491 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Mullen
  • Hand Surgery median
  • Middle half of Hand Surgery
  • National median

In program year 2025, general payments to James Mullen were reported at $2,528. Among 1,842 Hand Surgery profiles paid that year, the median was $270 and the middle half received between $102 and $1,118.

Show as a table
Year James Mullen Hand Surgery median Middle half National median
2019 $491 $383 $106–$1,905 $163
2020 $1,549 $172 $51–$1,268 $114
2021 $10,116 $263 $71–$1,591 $132
2022 $11,994 $336 $87–$1,938 $149
2023 $2,270 $233 $81–$1,114 $160
2024 $13,712 $258 $88–$1,203 $164
2025 $2,528 $270 $102–$1,118 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medartis Inc. $27,196 41 payments
  2. Trice Medical, Inc. $8,175 10 payments
  3. Mid-Atlantic Surgical Systems, LLC $3,425 6 payments
  4. Arthrex, Inc. $2,255 32 payments
  5. Medtronic USA, Inc. $366 3 payments
  6. Stryker Corporation $252 4 payments
  7. AxoGen $208 6 payments
  8. Smith+Nephew, Inc. $208 4 payments
  9. Suvon Surgical LLC $112 1 payment
  10. Pacira Pharmaceuticals Incorporated $100 1 payment
  11. Other $362 19 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $28,825 11 payments
  2. Food and Beverage $6,069 98 payments
  3. Travel and Lodging $3,185 15 payments
  4. Education $2,400 2 payments
  5. Honoraria $2,180 1 payment
Products named General payments · program years 2019–2025
  1. APTUS Ortho $21,168 27 payments
  2. APTUS Ortho $4,326 8 payments
  3. APTUS Ortho $1,702 6 payments
  4. O-ARM-Spine $269 2 payments
  5. REUNION $161 2 payments
  6. GRAFIX PL $143 1 payment
  7. AXOGUARD NERVE PROTECTOR $135 3 payments
  8. AxoGuard Nerve Connector $135 3 payments
  9. Exparel $100 1 payment
  10. MazorX - Renaissance $98 1 payment
  11. Other $749 36 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

21

Median for Orthopedic Surgery: 203

Drug cost

$149

Median for Orthopedic Surgery: $1,433

Branded share of claims

0%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Methylprednisolone Generic 21 $149

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 69 billing codes

Paid by Medicare

$75,870

Of which drugs: $779

Medicare patients

255

Average age 75

Services billed

3,009

156 women, 99 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 60%
Diabetes 27%
Depression 25%
Ischemic heart disease 24%
Chronic kidney disease 19%
Osteoporosis 18%
COPD 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 60 102 $522
Injection, methylprednisolone acetate, 1 mg J1010 Office 34 2,000 $202
Injection, methylprednisolone acetate, 40 mg J1030 Office 11 12 $50

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

127 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hand Surgery in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record